Navigation Links
A Biologic Drug Superior to Spiriva in Reducing COPD-Related Exacerbations Would Earn a Higher Patient Share in Europe Than in the U.S.
Date:1/12/2009

Spiriva Will Remain the Gold Standard Treatment Through 2017, According to a New Report from Decision Resources.

WALTHAM, Mass., Jan. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a biologic drug that is superior to Boehringer Ingelheim/Pfizer's Spiriva in reducing yearly COPD-related exacerbations would earn a higher patient share in Europe (30 percent) than in the U.S. (15 percent) according to surveyed European and U.S. pulmonologists. COPD-related exacerbations are episodic events often requiring hospitalization.

"A biological drug that provides fewer yearly COPD-related exacerbations compared to current therapies holds much commercial promise," said Regina Jammen, M.S., analyst at Decision Resources. "Enthusiasm from U.S. and European pulmonologists for a biologic drug with the potential to dramatically reduce yearly exacerbation rates likely reflects physicians' recognition of not only the long-term therapeutic benefits of such a drug, but also its economic benefits."

The new report entitled Chronic Obstructive Pulmonary Disease: Blockbuster Potential Exists for Biologic Drugs That Dramatically Reduce Exacerbation Rates finds that Spiriva will remain Decision Resources' clinical gold standard treatment for COPD over the next eight years even though emerging drugs such as Forest/Almirall's aclidinium, Novartis's indacaterol, Boehringer Ingelheim's BI-1744/tiotropium and Nycomed/Mitsubishi Tanabe's roflumilast will offer therapeutic benefits to COPD patients.

About the Report

Chronic Obstructive Pulmonary Disease: Blockbuster Potential Exists for Biologic Drugs That Dramatically Reduce Exacerbation Rates is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.DecisionResources.com ) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com .

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biologic treatment for rheumatoid arthritis and the risk of cancer
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Neurobiological Technologies Reports Going Concern Qualification
4. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
5. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
6. Study questions assumptions about human sensitivity to biological motion
7. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
8. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
9. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
10. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
11. CalbaTech Reports That LifeStems Biologics License Has Been Renewed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... ... and ergoFET force gauges used in physical therapy, occupational therapy and sports medicine ... for resistance cord exercise and therapy, introduces its new microFET Digital Pinch Gauge. ...
(Date:2/11/2016)... , ... February 11, 2016 , ... As part of ... of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to University of ... Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support a promising ...
(Date:2/10/2016)... ... ... LaserShip, a regional parcel carrier that services the eastern U.S., donated and delivered ... order to aid in the Flint water crisis. In 2014, LaserShip acquired Prestige Delivery ... only 15 miles away from Flint. , “We have deep roots in the local ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting ... Healthcare, recently partnered with Heart City Health Center to improve access ... years, Heart City Health Center has provided the Elkhart community with access to ...
(Date:2/10/2016)... SAN FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... category: Best Water Brand. There were three leading bottled water brand owners that topped ... edge services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... development of a once-daily, oral therapy for the treatment ... Officer, Dr. Maya Halpern , has notified the Company ... Officer and from its Board of Directors effective as ... age. Allen Baharaff . Mr. Baharaff continued, ...
(Date:2/11/2016)... Germany , February 11, 2016 ... up 6.8% to EUR 1,377.2m  Adjusted EBITDA climbs to ... 18.0% to EUR 3.41  Proposed dividend of EUR 0.85 ... sale of glass tubing business and refinancing successfully completed  ... to 5% on organic basis  Adjusted EBITDA expected ...
(Date:2/10/2016)... in the U.S. and Europe , announced ... laser at the upcoming 151 st Midwinter Meeting of ... #4815. The ST PRO is a full featured hard and ... the award winning, industry leading Lightwalker ATS. At an introductory price ... attractive to many dentists hesitating to incorporate lasers into their ...
Breaking Medicine Technology: